Banc of America Starts Acorda Therapeutics (ACOR) at Buy
More News related to ACOR
- Leerink Swann Upgrades Acorda Therapeutics (ACOR) Two-Notches to Outperform
- Acorda (ACOR) CEO On CNBC
- Acorda (ACOR) Enters License Agreement With Biogen Idec (BIIB) For Fampridine-SR Outside the U.S.
- Biogen Idec and Acorda Therapeutics Announce Collaboration Agreement to Develop and Commercialize MS Therapy Fampridine-SR in Markets Outside the U.S.
- Acorda Therapeutic (ACOR) October volatility at 93 into PDUFA
More News related to New Coverage
- Bank of America Resumes Coverage on Bristol-Myers (BMY) with a Neutral
- Credit Suisse Resumes Coverage on Rio Tinto (RTP) with an Outperform
Banc of America initiates coverage on Acorda Therapeutics (Nasdaq: ACOR) with a Buy rating and $24 price target.
Acorda Therapeutics is a biotechnology company developing therapies for SCI, MS and related nervous system disorders. The Company's marketed products include Zanaflex Capsules, a short-acting drug indicated for the management of spasticity. Acorda's lead clinical stage product, Fampridine-SR, recently completed a Phase 3 study in people with MS.
Related Categories
New CoverageStocks Mentioned
-0.25Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
